• Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

  • Jan 16 2024
  • Duración: 33 m
  • Podcast

Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.

    Más Menos
Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles